Computational design of a novel multi-epitope vaccine candidate against group A rotavirus

Area of Science:

• Vaccinology
• Computational Biology
• Immunology

Background:

• Rotavirus A (RVA) is a leading cause of diarrhea-related mortality in children under five.
• Current live attenuated RVA vaccines have limitations, necessitating alternative vaccine development.

Purpose of the Study:

• To design a novel multi-epitope vaccine against RVA utilizing reverse vaccinology.
• To computationally assess the immunogenicity and efficacy of the designed vaccine candidate.

Main Methods:

• Reverse vaccinology approaches were employed to identify and link conserved B-cell and T-cell epitopes from RVA VP6.
• 50S ribosomal protein L12 was incorporated as an adjuvant.
• In silico analyses including antigenicity, allergenicity, toxicity, physicochemical properties, molecular docking, molecular dynamics simulations, and immune response simulations were performed.
• Expression feasibility in Escherichia coli was evaluated.

Main Results:

• The designed multi-epitope vaccine candidate demonstrated favorable antigenicity, allergenicity, toxicity, and physicochemical profiles.
• Molecular docking and dynamics simulations revealed strong binding interactions with TLR4, suggesting enhanced antigen presentation.
• Immunity simulations indicated a significant increase in immunoglobulins and cytokines.
• High likelihood of successful expression in E. coli was predicted.

Conclusions:

• The in silico designed multi-epitope RVA vaccine candidate shows significant potential for inducing a robust immune response.
• Further experimental validation is crucial to confirm the vaccine's immunogenicity and protective efficacy against Rotavirus A.